Company Analysis
Sign in

Nanobiotix S.A. (NBTX)

Nasdaq: NBTX · Pharmaceutical Preparations · Paris, FR · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.8
◀ Past 5.6● Present 5.4▶ Future 6.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Nanobiotix S.A.

Nine metrics read from its own filings, by tense
Headline grade
5.8/10
◀ Past5.630% of the headline
● Present5.440% of the headline
▶ Future6.630% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.6/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2018.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Nanobiotix S.A.'s filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.4/10

What has it actually done, year after year?

+37.7% a year over 8 filed years; profitable in 0 of 8.

weight 45% of this tense · 34th percentile among 323 sector filers · read for its customers

From the record

Nanobiotix S.A.'s 8 filed years say what it did: revenue went from EUR 3 million in fiscal 2018 to EUR 33 million in fiscal 2025, up 37.7% a year; it rose in 3 of 6 years; the deepest fall was 120% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 8 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span37.7%top 27% of its family
  • the share of years revenue rosebottom 36% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak119.9%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
6.2/10

How has it treated the people who own it?

SI estimate 6.2/10, confidence 35 of 100 (one part).

weight 22% of this tense · 62nd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 38% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Nanobiotix S.A.'s shareholder treatment is put at 6.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 38% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
4.3/10

Is it financially healthy right now?

Leverage 225%: owes 225¢ per asset dollar.

weight 45% of this tense · 43rd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Nanobiotix S.A.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 225 cents per dollar of assets, and net share issuance: its share count grew 1.2% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 3% of its family
  • the share count against the year beforetop 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
7.1/10

How strong is its position in its industry?

top 29% of 315 in its family; net margin -73.5%.

weight 33% of this tense · 71st percentile among 315 sector filers · read for its customers

From the record

Nanobiotix S.A.'s standing among 315 graded names in its industry family: revenue of EUR 33 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -73.5% ranks in the top 43%; revenue growth of 89.7% a year over the last 3 filed years ranks in the top 15% (its annual reports).

What it rests on

  • net margin-73.5%top 43% of its family
  • three-year revenue growth89.7%top 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned
family median, 371 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Nanobiotix S.A.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.6/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
5.8/10

How much room does it have to grow?

top 42% of 273 in its family for room to expand.

weight 45% of this tense · 58th percentile among 273 sector filers · read for itself

From the record

Nanobiotix S.A.'s room to grow, from the newest filed statements (fiscal 2025): cash of EUR 53 million against no long-term debt tagged leaves 77.8% of its assets as net cash, top 19% of its family; cash from operations less capital spending is -104.2% of revenue (bottom 49%); research spending of 70.9% of revenue (bottom 46%) (its annual report).

What it rests on

  • cash less debt against assets77.8%top 19% of its family
  • cash from operations less capital spending against revenue-104.2%bottom 49% of its family
  • research spending against revenue70.9%bottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
7.0/10

What could actually drive growth from here?

top 30% of 306 in its family for growth drivers.

weight 33% of this tense · 70th percentile among 306 sector filers · read for its customers

From the record

Nanobiotix S.A.'s growth drivers, from the filed years to fiscal 2025: revenue grew 89.7% a year over the last three filed years against 37.7% over all 8, speeding up (top 8% of its family); research spending grew -10.9% a year (bottom 29%); capital spending grew 80.1% a year (top 11%) (its annual reports). Nanobiotix S.A. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+52.0 points a yeartop 8% of its family
  • three-year growth of research spending-10.9%bottom 29% of its family
  • three-year growth of capital spending80.1%top 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
7.7/10

Did its newest year beat what its own record pointed to?

top 23% of 233 in its family for expectations against reality.

weight 22% of this tense · 77th percentile among 233 sector filers · read for its shareholders

From the record

Nanobiotix S.A.'s newest year against its own record: net income of EUR 24 million against a prior three-year average of EUR 55 million (top 29%); a net margin of -73.5% against losses larger than its revenue before (top 18%) (its annual reports).

What it rests on

  • net income against the prior three years' average+56%top 29% of its family
  • net margin against its prior averageup more than 100 pointstop 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NBTX · research, not advice